Zobrazeno 1 - 10
of 74
pro vyhledávání: '"D Bruce Fulton"'
Publikováno v:
eLife, Vol 9 (2020)
Bruton’s tyrosine kinase (BTK) is targeted in the treatment of B-cell disorders including leukemias and lymphomas. Currently approved BTK inhibitors, including Ibrutinib, a first-in-class covalent inhibitor of BTK, bind directly to the kinase activ
Externí odkaz:
https://doaj.org/article/a1e7c59bd7424b1ea7e5693fd82af544
Autor:
John R. Engen, Wayland Yeung, Amy H. Andreotti, Natarajan Kannan, Raji E. Joseph, Thomas E. Wales, Annie Kwon, Neha Amatya, D. Bruce Fulton
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance Bruton’s tyrosine kinase (BTK) is targeted in treatment of immune cancers. As patients experience drug resistance, there is a need for alternative approaches to inhibit BTK. Other recently published findings clarify the role of the BTK
Autor:
Vibeke Sundvold-Gjerstad, Stine Granum, Anne Spurkland, Thorny Cecilie Bie Andersen, B. Göran Karlsson, Morten Sørli, Amy H. Andreotti, Paul Hoff Backe, Per Eugen Kristiansen, Maria U. Johansson, D. Bruce Fulton, Zsuzsa Huszenicza, Hanna Kjelstrup, Ramakrishna Prabhu Gopalakrishnan, Scott E. Boyken
Publikováno v:
Journal of Biological Chemistry
J Biol Chem
15480-15494
J Biol Chem
15480-15494
T-cell activation requires stimulation of specific intracellular signaling pathways in which protein-tyrosine kinases, phosphatases, and adapter proteins interact to transmit signals from the T-cell receptor to the nucleus. Interactions of LCK proto-
Autor:
Raji E. Joseph, Jacques Lowe, D. Bruce Fulton, John R. Engen, Thomas E. Wales, Amy H. Andreotti
Publikováno v:
J Mol Biol
Mutations in PLCγ, a substrate of the tyrosine kinase BTK, are often found in patients who develop resistance to the BTK inhibitor Ibrutinib. However, the mechanisms by which these PLCγ mutations cause Ibrutinib resistance are unclear. Under normal
Autor:
D. Bruce Fulton, Amy H. Andreotti, Thomas E. Wales, Neha Amatya, John R. Engen, Raji E. Joseph
Publikováno v:
eLife, Vol 9 (2020)
eLife
eLife
Bruton’s tyrosine kinase (BTK) is targeted in the treatment of B-cell disorders including leukemias and lymphomas. Currently approved BTK inhibitors, including Ibrutinib, a first-in-class covalent inhibitor of BTK, bind directly to the kinase activ
Publikováno v:
Biochemistry. 56:2938-2949
Pleckstrin homology (PH) domains are well-known as phospholipid binding modules, yet evidence that PH domain function extends beyond lipid recognition is mounting. In this work, we characterize a protein binding function for the PH domain of interleu
Autor:
Jagannathan Alagurajan, Mark S. Hargrove, Navjot Singh Athwal, Amy H. Andreotti, Ryan Sturms, D. Bruce Fulton
Publikováno v:
Journal of Inorganic Biochemistry. 150:139-147
Hemoglobins (phytoglobins) from rice plants (nsHb1) and from the cyanobacterium Synechocystis (PCC 6803) (SynHb) can reduce hydroxylamine with two electrons to form ammonium. The reaction requires intermolecular electron transfer between protein mole
Summary Capturing the functionally relevant forms of dynamic, multidomain proteins is extremely challenging. Bruton's tyrosine kinase (BTK), a kinase essential for B and mast cell function, has stubbornly resisted crystallization in its full-length f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d3edbd65b5cf1100d99130d2c9e940b
https://europepmc.org/articles/PMC5629114/
https://europepmc.org/articles/PMC5629114/
Autor:
Scott E. Boyken, Amy H. Andreotti, Nikita Chopra, John R. Engen, Qian Xie, Raji E. Joseph, Thomas E. Wales, D. Bruce Fulton, Robert L. Jernigan
Publikováno v:
Journal of Molecular Biology. 426:3656-3669
Despite high level of homology among non-receptor tyrosine kinases, different kinase families employ a diverse array of regulatory mechanisms. For example, the catalytic kinase domains of the Tec family kinases are inactive without assembly of the ad